Clinical Trials · NCT05163106
Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- University Hospital, Akershus
- Enrollment
- 85
- Start date
- Dec 2022
- Locations
- 1 site, Norway
- Primary endpoint
- To study the change in levels of direct and indirect immunologic biomarkers of targeted cancer therapy with letrozole and ribociclib given in combination for patients with locally-advanced, ER-positive, HER-2 negative, luminal A7B breast cancer